8 / 14
Page 19
Notes:
Journal of Brain and Neurology | Volume 3
allied
academies
March 14-16, 2019 | London, UK
12
th
International Conference on
8
th
International Conference on
Vascular Dementia and Dementia
Neurological Disorders and Stroke
Joint Event
&
T
echnology’s causing treatment paradigms to be
reconsidered. Previously, it was almost impossible to match
treatment with cognitive and behavioral changes. Now Digital
Therapeutics and Digiceuticals enable more flexible treatment
and monitoring alternatives.
Digital Therapeutics is defined as immersive programs that
act reliably and remotely to change individual’s behaviors to
achieve positive clinical outcomes and reduce medical cost
growth. They’re often used in conjunction with medication
but may replace conventional prescribing. Digi Pharma is
consumer focused, such as nutritional supplements. They’re
typically not reimbursed, FDA/NHS authorized and low priced,
with consumers paying directly after marketing discovery.
ReMe discovers personal content through interactive response
to activities, that positively impacts on behavior and calms
agitation, reducing or complimenting the use of medication.
This unique new data set called ELR (Electronic Life Records)
enables personalizing activities such that
ReMe is definable as the world’s first elderly and dementia
Digi therapeutic, by reducing premature resort to medication
through knowing the content that reduces agitation and
delivering activities that optimize engagement. ReMe achieves
improved wellbeing, shows a propensity to support cognitive
retention and recall and can be used in therapy and acute
care strategies. So, in terms of definition, ReMe falls into both
categories, subject to the deployment used.
Current studies in Kingston Hospital, London, aim to establish
ReMe’s potential to reduce medication, improve admission
processes, enhance person centered care, as well as achieve
efficiency and cost savings through digital reporting, reduced
staffing, earlier discharge and optimal step down. If it can be
shown that ReMe’s digital intervention achieve these outcomes
then this dual role of Digi Pharma in the community and
Digi therapy in the formal care setting, warrants ReMe being
prescribed either as a supplement or alternative to traditional
medication. ReMe enables the transfer of GDPR compliant
personal data across health and social care sectors and supports
connectivity between the people cared for, family, care home
and ward, thereby impacting on the key issues of independent
and assisted living, better residential care and bed blocking in
hospitals. The impact of digital prescribing on cost savings could
be substantial and as a result business payment models will
be developed that fit the new treatments. Answers will come
when the evidence is there. ReMe offers an insight into what
one new treatment configuration of the future could look like.
Speaker Biography
Simon Hooper, co-founder of RemindMeCare. He has a tech background that is
non-medical but which he has brought to bear on the care process, courtesy of his
experience with the care needs of his family. Supported by academia and health
care professionals, ReMe is the result of extensive work in numerous care settings.
The company has worked closely with care facilities, day care centers and hospitals to
create systems that are directed at improving care delivery.
e:
simon@health-connected.comSimon Hooper
Health-Connected Ltd (RemindMeCare), UK
New trends in the use of digital interventions in care: Digi therapeutics and electronic
life records